Strategic investors Aetna and Horizon Healthcare Services were among the investors in a $36.6m round that took AbleTo's total funding to more than $57m.

University of Massachusetts Medical School spinoff Apic Bio has raised seed capital from The Alpha-1 Project as it looks to develop a treatment for Alpha-1 Antitrypsin deficiency.

The skin disease therapy developer has filed for a $34.5m initial public offering, days after raising $11.3m in a Sun Pharmaceutical Industries-led round.

BioTime has contributed to a $10m round for AgeX, an age-related disease treatment developer it has spun out that is now valued at $68m.

Mitsui and corporate venturing units Robert Bosch Venture Capital and Ascension Health Ventures had helped provide $60m to the Aethon, which is set to be acquired by VTLS.

Becton, Dickinson and Company has participated in a round that took the GE Ventures-backed medication analysis technology provider's total funding to $8m.

Anti-aging therapeutics developer Unity Biotechnology has added $35m to a WuXi PharmaTech and Mayo Clinic-backed series B round that it has now closed at $151m.